In addition, a 16-week double-blind study showed that tofogliflozin exerted beneficial effects in subjects with T2DM whose HbA1c levels were poorly controlled with insulin monotherapy or insulin plus a DPP-4 inhibitor [23]. Here, DPP4 is linked to type 2 diabetes mellitus.